Hamza Ismail, MD
Internal Medicine · Iowa City, IANPI 1962693903
Payments from drug & device makers
Across 53 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$227
- Bayer$128
- Abbott$108
- GSK$89
- AbbVie$57
- Amgen$53
- plus $397 from 16 others
What the payments were for
- Food & beverage$1,059100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $227 |
| Bayer | 4 | $128 |
| Abbott | 6 | $108 |
| GSK | 2 | $89 |
| AbbVie | 3 | $57 |
| Amgen | 3 | $53 |
| Lilly USA, LLC | 3 | $45 |
| Pfizer | 2 | $41 |
| Boston Scientific | 3 | $41 |
| AstraZeneca(2 entities) | 2 | $37 |
| Boehringer Ingelheim | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Antares Pharma, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Novartis | 1 | $13 |
How this compares
$1,059 in reported general payments places this provider in the 85th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 372 | $438,460 |
| EliquisApixaban | 138 | $116,576 |
| MounjaroTirzepatide | 75 | $110,909 |
| RybelsusSemaglutide | 43 | $84,645 |
| XareltoRivaroxaban | 56 | $71,918 |
| TrulicityDulaglutide | 26 | $36,353 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $33,936 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 44 | $31,656 |
| MyrbetriqMirabegron | 49 | $31,573 |
| FarxigaDapagliflozin Propanediol | 23 | $28,517 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $27,249 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 45 | $21,682 |
| LinzessLinaclotide | 25 | $20,418 |
| JanuviaSitagliptin Phosphate | 12 | $15,449 |
| OzempicSemaglutide | 11 | $14,776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat | $33 | $470,116416 claims |
| Lilly USA, LLCMounjaro, Trulicity | $45 | $147,262101 claims |
| PfizerEliquis | $41 | $116,576138 claims |
| Novo NordiskRybelsus, Ozempic | $227 | $99,42154 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $89 | $79,135149 claims |
| Johnson & JohnsonXarelto | $16 | $71,91856 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $37 | $46,98970 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $31,57349 claims |
| AbbVieLinzess, Savella | $57 | $26,23439 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $15 | $8,72413 claims |
| NovartisEntresto | $13 | $8,58313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Iowa City
- Madalyn WalshIowa City$80K
- Aziz HammoudIowa City$29K
- Mohammed MhannaIowa City$15K
- Sruti Prathivadhi-BhayankaramIowa City$6K
- Ankur MishraIowa City$3K
- Stephanie IvinsIowa City$2K
- Aneet KaurIowa City$2K
- Kathleen JonesWest Des Moines$7.6M
- Jennifer KillionAmes,$4.9M
- Lena Rydberg FreeseWest Des Moines$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.